001     294661
005     20241125182701.0
024 7 _ |a 10.1007/s00432-024-06019-3
|2 doi
024 7 _ |a pmid:39516427
|2 pmid
024 7 _ |a pmc:PMC11549193
|2 pmc
024 7 _ |a 0301-1585
|2 ISSN
024 7 _ |a 0084-5353
|2 ISSN
024 7 _ |a 0171-5216
|2 ISSN
024 7 _ |a 1432-1335
|2 ISSN
037 _ _ |a DKFZ-2024-02396
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Erdmann, Friederike
|b 0
245 _ _ |a Impact of the COVID-19 pandemic on cancer diagnoses, oncological care and cancer patients in Germany: a report from the 'COVID & Cancer' workshop 2023 of the German Society for Epidemiology (DGEpi).
260 _ _ |a Heidelberg
|c 2024
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1732535311_8025
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #LA:C071#LA:M110#
520 _ _ |a The COVID-19 pandemic was associated with severe disruptions in healthcare worldwide. Cancer patients are at particular risk of adverse consequences from delays in diagnosis and treatment. To evaluate the available data on the impact of the pandemic on cancer diagnoses, oncological care and patient well-being in Germany, the German Society for Epidemiology (DGEpi) in collaboration with the Epidemiological Cancer Registry of Lower Saxony invited to a workshop on 'COVID & Cancer' (held on 26-27 October 2023 in Hanover, Germany). This report provides a summary of the scientific presentations, highlights methodological challenges, and recognises essential evidence gaps.Twelve studies addressing various aspects in relation to cancer diagnoses, oncological care and patient well-being during the COVID-19 pandemic in Germany and two talks sharing experiences from the UK and the Netherlands were presented at the workshop.Results from German cancer registries consistently showed lower number of incident cancer diagnoses among adults during the first months of the pandemic compared to the respective months of the years before the pandemic. Data from the cancer registries of Baden-Württemberg and Lower Saxony found especially for breast cancer a notable drop (by approximately one third) in the numbers of diagnoses during the first restriction period (April-May 2020), during which the nationwide mammography screening programme in Germany was temporarily suspended. Overall, the extent and ways, in which the pandemic had adversely affected cancer diagnoses, oncological care and created service backlogs, is still not adequately understood. The long-term consequences are yet to be determined.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Adverse consequences
|2 Other
650 _ 7 |a COVID-19 pandemic
|2 Other
650 _ 7 |a Cancer care
|2 Other
650 _ 7 |a Delayed diagnosis
|2 Other
650 _ 7 |a Germany
|2 Other
650 _ 7 |a Incidence
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a COVID-19: epidemiology
|2 MeSH
650 _ 2 |a Germany: epidemiology
|2 MeSH
650 _ 2 |a Neoplasms: epidemiology
|2 MeSH
650 _ 2 |a Neoplasms: diagnosis
|2 MeSH
650 _ 2 |a Neoplasms: therapy
|2 MeSH
650 _ 2 |a Registries
|2 MeSH
650 _ 2 |a SARS-CoV-2
|2 MeSH
650 _ 2 |a Medical Oncology: methods
|2 MeSH
650 _ 2 |a Pandemics
|2 MeSH
650 _ 2 |a Female
|2 MeSH
700 1 _ |a Wellbrock, Maike
|b 1
700 1 _ |a De Santis, Karina Karolina
|b 2
700 1 _ |a Hübner, Joachim
|b 3
700 1 _ |a Voigtländer, Sven
|b 4
700 1 _ |a Arndt, Volker
|0 P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0
|b 5
|e Last author
|u dkfz
773 _ _ |a 10.1007/s00432-024-06019-3
|g Vol. 150, no. 11, p. 491
|0 PERI:(DE-600)1459285-X
|n 11
|p 491
|t Journal of cancer research and clinical oncology
|v 150
|y 2024
|x 0301-1585
909 C O |o oai:inrepo02.dkfz.de:294661
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2024
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CANCER RES CLIN : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-21
920 2 _ |0 I:(DE-He78)C071-20160331
|k C071
|l C071 Cancer Survivorship
|x 0
920 2 _ |0 I:(DE-He78)M110-20160331
|k M110
|l M110 Epidemiologisches Krebsregister BW
|x 1
920 1 _ |0 I:(DE-He78)C071-20160331
|k C071
|l C071 Cancer Survivorship
|x 0
920 1 _ |0 I:(DE-He78)M110-20160331
|k M110
|l M110 Epidemiologisches Krebsregister BW
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C071-20160331
980 _ _ |a I:(DE-He78)M110-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21